Cardiol Therapeutics Files 6-K with Meeting Notice
Ticker: CRDL · Form: 6-K · Filed: Mar 14, 2025 · CIK: 1702123
Sentiment: neutral
Topics: corporate-action, meeting-notice, filing
Related Tickers: CRDL
TL;DR
Cardiol Therapeutics (CRDL) filed a 6-K for a March 14th meeting notice - watch for shareholder votes.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on March 14, 2025, reporting a Notice of Meeting and Record Date dated March 14, 2025. The company, headquartered in Oakville, Ontario, Canada, is involved in the biological products sector. Chris Waddick, Chief Financial Officer, signed the report.
Why It Matters
This filing indicates upcoming corporate actions or decisions requiring shareholder participation, potentially impacting the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine procedural document (Notice of Meeting) and does not contain new financial or operational risks.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- March 14, 2025 (date) — Filing date and Notice of Meeting date
- Chris Waddick (person) — Chief Financial Officer
- Oakville, Ontario L6H 0G5 Canada (location) — Principal executive office address
FAQ
What is the purpose of the Notice of Meeting and Record Date filed as Exhibit 99.1?
The filing does not specify the purpose of the meeting, only that a Notice of Meeting and Record Date was issued on March 14, 2025.
When was this Form 6-K filed with the SEC?
The Form 6-K was filed on March 14, 2025.
Who signed the Form 6-K on behalf of Cardiol Therapeutics Inc.?
Chris Waddick, Chief Financial Officer, signed the Form 6-K.
What is Cardiol Therapeutics Inc.'s primary business sector?
Cardiol Therapeutics Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
What is the principal executive office address of Cardiol Therapeutics Inc.?
The principal executive office is located at 602-2265 Upper Middle Road East, Oakville, Ontario L6H 0G5, Canada.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 14, 2025 by Chris Waddick regarding Cardiol Therapeutics Inc. (CRDL).